Table 4.

Results of univariate logistic regression analysis to identify factors that are independently associated with antiviral efficacy.

Parameter	HBV DNA undetectability			Low HBsAg concentration			HBsAg loss			HBeAg loss
	Odds ratio	95% CI	P-value	Odds ratio	95% CI	P-value	Odds ratio	95% CI	P-value	Odds ratio	95% CI	P-value
Age	0.965	0.923–1.008	0.112	0.980	0.933–1.028	0.406	0.983	0.900–1.075	0.712	0.944	0.895–0.995	0.032
Sex (Female)	0.577	0.281–1.103	0.093	0.872	0.453–1.680	0.683	0.777	0.209–2.886	0.706	2.411	1.083–5.365	0.031
Baseline HBsAg concentration (log10 IU/mL)	0.467	0.193–1.126	0.090	1.000	1.000–1.000	0.861	1.000	1.000–1.000	0.156	1.000	1.000–1.000	0.470
Baseline HBeAg (positive vs. negative)	0.932	0.409–2.123	0.866	0.757	0.322–1.783	0.525	0.954	0.210–4.331	0.951
Baseline HBV DNA concentration (log10 copies/mL)	1.000	0.998–1.001	0.644	1.000	1.000–1.000	0.385	1.000	1.000–1.000	0.837	1.000	1.000–1.000	0.899
IFN regimen (short-acting vs. long-acting)	1.384	0.737–2.597	0.312	0.964	0.496–1.874	0.914	0.809	0.214–3.053	0.754	1.205	0.596–2.435	0.604
Thyroid function (abnormal)	0.781–2.618	0.860–3.936	0.247	1.124	0.608–2.077	0.709	5.407	1.354–21.596	0.017	1.075	0.550–2.102	0.832
Duration of treatment (weeks)	1.022	0.952–1.097	0.543	1.055	0.979–1.136	0.160	1.156	0.955–1.399	0.138	0.997	0.922–1.077	0.932
Patients with an early interruption of IFN treatment (n, %)	1.059	0.245–4.577	0.939	2.222	0.499–9.908	0.295	9.365	0.371–236.295	0.174	0.621	0.121–3.176	0.567
End-of-treatment HBsAg (log10 IU/mL)	1.291	0.860–1.938	0.218	1.508	0.971–2.341	0.067	1.190	0.465–3.050	0.717	1.204	0.776–1.868	0.408
Baseline ALT activity (U/L)	1.004	1.002–1.007	<0.001	1.001	0.999–1.003	0.426	1.000	0.997–1.004	0.785	1.001	0.999–1.003	0.556

P-values < 0.05 are shown in bold and italics.

HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B envelope antigen; HBV, hepatitis B virus; IFN, interferon; ALT, alanine aminotransferase; CI, confidence interval.